We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+12.59%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$18.9B
AUM Growth
+$3.55B
(+23%)
Cap. Flow
+$2.11B
Cap. Flow
% of AUM
11.15%
Top 10 Holdings %
Top 10 Hldgs %
14.56%
Holding
1,090
New
199
Increased
468
Reduced
192
Closed
179
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$216M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$129M |
| 3 |
Brown & Brown
BRO
|
+$121M |
| 4 |
Arthur J. Gallagher & Co
AJG
|
+$116M |
| 5 |
AKRO
Akero Therapeutics
AKRO
|
+$90.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$144M |
| 2 |
MetLife
MET
|
+$97.2M |
| 3 |
Travelers Companies
TRV
|
+$91.9M |
| 4 |
Electronic Arts
EA
|
+$91.9M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$76M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.08% |
| 2 | Technology | 23.91% |
| 3 | Financials | 10.59% |
| 4 | Consumer Discretionary | 9.42% |
| 5 | Industrials | 7.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SLNO
201
DELISTED
Soleno Therapeutics
SLNO
| $29.3M | 0.15% |
349,664
| – | – |
|
202
Ionis Pharmaceuticals
IONS
$8.6B
| $29M | 0.15% |
+732,813
| New | +$24M |
|
203
Mirum Pharmaceuticals
MIRM
$6.46B
| $28.9M | 0.15% |
567,894
+1,623
| +0.3% | +$72.3K |
|
204
RB Global
RBA
$20.4B
| $28.7M | 0.15% |
270,309
+229,402
| +561% | +$23.5M |
|
205
Janux Therapeutics
JANX
$925M
| $28.7M | 0.15% |
1,241,938
-215,157
| -15% | -$5.67M |
|
|
VRNA
206
DELISTED
Verona Pharma
VRNA
| $28.5M | 0.15% |
300,827
| – | – |
|
207
Workiva
WK
$3.36B
| $28.5M | 0.15% |
415,633
+115,120
| +38% | +$7.92M |
|
208
Tyson Foods
TSN
$20.4B
| $28.4M | 0.15% |
507,357
+483,179
| +1,998% | +$27.8M |
|
209
Wells Fargo
WFC
$261B
| $28.2M | 0.15% |
352,001
+74,138
| +27% | +$5.35M |
|
|
SEE
210
DELISTED
Sealed Air
SEE
| $28M | 0.15% |
901,255
+288,415
| +47% | +$8.58M |
|
211
monday.com
MNDY
$3.68B
| $27.9M | 0.15% |
+88,795
| New | +$24.7M |
|
212
TransDigm Group
TDG
$70.2B
| $27.7M | 0.15% |
18,202
+11,843
| +186% | +$16.6M |
|
213
Crown Holdings
CCK
$12.8B
| $27.6M | 0.15% |
268,138
+197,478
| +279% | +$18.8M |
|
214
Incyte
INCY
$24.2B
| $27.5M | 0.15% |
403,864
-400,191
| -50% | -$25.4M |
|
215
Americold
COLD
$4.02B
| $27.2M | 0.14% |
1,633,745
-157,768
| -9% | -$2.86M |
|
216
Shake Shack
SHAK
$2.53B
| $27.2M | 0.14% |
193,128
+176,209
| +1,041% | +$19.2M |
|
217
Pentair
PNR
$10.4B
| $27M | 0.14% |
262,749
-397,817
| -60% | -$37.1M |
|
218
On Holding
ONON
$12.1B
| $26.9M | 0.14% |
516,543
+532
| +0.1% | +$27.1K |
|
219
Mohawk Industries
MHK
$7.5B
| $26.7M | 0.14% |
255,050
+98,458
| +63% | +$10.3M |
|
220
Quest Diagnostics
DGX
$25.7B
| $26.7M | 0.14% |
148,473
-232,227
| -61% | -$40.3M |
|
221
Vulcan Materials
VMC
$34.8B
| $26.6M | 0.14% |
101,861
-99,912
| -50% | -$25.7M |
|
222
Nike
NKE
$61.9B
| $26.5M | 0.14% |
373,335
+273,538
| +274% | +$16.4M |
|
223
Seagate
STX
$194B
| $26.5M | 0.14% |
183,527
+164,747
| +877% | +$17.1M |
|
224
Ecolab
ECL
$78.1B
| $26.5M | 0.14% |
98,308
+77,016
| +362% | +$19.6M |
|
225
Hershey
HSY
$35.2B
| $26.2M | 0.14% |
158,012
+145,530
| +1,166% | +$24M |
|
Similar funds
PAM
TCIIS
UIM
Woodline Partners's Q2 2025 Portfolio in Review
As of Q2 2025, Woodline Partners held 1,090 positions worth $18.9B, up 23% from $15.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Woodline Partners deployed $2.11B of net new capital in Q2 2025, opening 199 new positions and adding to 468 existing holdings. Its largest new stake was Brown & Brown: 1,079,076 shares worth $120M.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 30% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $76M trimmed.
- Woodline Partners's largest Q2 2025 buy was Brown & Brown: 1,079,076 shares worth $120M.
- Woodline Partners added most to Microsoft in Q2 2025, an estimated $216M increase.
- Woodline Partners's biggest Q2 2025 reduction was SpringWorks Therapeutics, cutting an estimated $76M.
- Woodline Partners fully exited Lam Research in Q2 2025, selling an estimated $144M.
- Woodline Partners's ten largest holdings make up 15% of its $18.9B portfolio in Q2 2025.
- Woodline Partners opened 199 new positions and closed 179 in Q2 2025.
- Woodline Partners's portfolio value rose 23% quarter-over-quarter to $18.9B.
Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.